DDInter1744 DDInter1676
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Tamoxifen {u} (Compound) resembles {v} (Compound) Methadyl Acetate
Tamoxifen {u} may lead to a major life threatening interaction when taken with {v} Dextropropoxyphene
Tamoxifen {u} (Compound) resembles {v} (Compound) Naftifine
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loperamide
Tamoxifen {u} may lead to a major life threatening interaction when taken with {v} Diphenhydramine
Tamoxifen {u} (Compound) treats {v} (Disease) breast cancer
Tamoxifen {u} (Compound) binds {v} (Gene) CYP2E1
Tamoxifen {u} (Compound) upregulates {v} (Gene) SC5D
Tamoxifen {u} (Compound) downregulates {v} (Gene) CCNB2
Tamoxifen {u} (Compound) causes {v} (Side Effect) Thirst
Tamoxifen (Compound) resembles Methadyl Acetate (Compound)
Tamoxifen may lead to a major life threatening interaction when taken with Dextropropoxyphene
Tamoxifen (Compound) resembles Naftifine (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Tamoxifen may lead to a major life threatening interaction when taken with Diphenhydramine
Tamoxifen (Compound) treats breast cancer (Disease)
Tamoxifen (Compound) binds CYP2E1 (Gene)
Tamoxifen (Compound) upregulates SC5D (Gene)
Tamoxifen (Compound) downregulates CCNB2 (Gene)
Tamoxifen (Compound) causes Thirst (Side Effect)